Immunoinformatics design and in vitro evaluation of dendritic cell-targeting brucellosis multi-epitope vaccine based on Omp28 and GroEL
Researchers have developed a multi-epitope vaccine candidate for brucellosis using reverse vaccinology and dendritic cell-targeting peptides. In vitro tests indicate the vaccine is stable and capable of eliciting a strong immune response against the zoonotic disease.
Why it matters
Brucellosis affects millions globally, and the lack of a safe human vaccine makes this research a critical step toward public health prevention.
Scientific Reports ( 2026 ) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in